News All News

In a recent Guppy Tank event, Professor Jeffrey Smith received feedback from a panel of investors on a new molecule that could help most sun-sensitive patients, research supported by the Blavatnik Biomedical Accelerator. Harvard's Office of Technology Development and LabCentral co-host the Guppy Tank series, where innovators pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

Attivare, a startup advancing a portfolio of technologies developed at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Massachusetts General Hospital, has shown promising results in cancer clinical trials and is developing a malaria vaccine. Through decades of innovation and cross-disciplinary collaboration, the technology has the potential to fight cancer more effectively or prevent pathogen-related infections. 

For more than three decades, Greg Verdine has brought bold, innovative methods to solving some of medicine’s biggest challenges - from early-stage work backed by the Harvard Blavatnik Biomedical Accelerator to the launch of multiple startups.

Researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences built a device called a pico-calorimeter that directly measures heat signals from small groups of living cells. The device could lead to advances in bacterial growth monitoring or antibiotic resistance testing.